COVID-19 Vaccine –Associated Myocarditis Considerations for Competitive Athletes

AbstractPurpose of reviewTo review the epidemiology of COVID-19 vaccine –associated myocarditis (VAM), evaluation of athletes with suspected VAM, and safe return to play for athletes with confirmed VAM.Recent findingsVAM is a rare complication of COVID-19 vaccination, with pretest probability highest in those who experience chest pain within several days after messenger RNA vaccine administration. While data from young athletes with VAM are lacking, the initial evaluation for those with high pre-test probability of  VAM includes ECG, echocardiography, and troponin testing. Those with abnormal testing warrant cardiac magnetic resonance imaging to confirm the diagnosis of VAM. Athletes with confirmed VAM should be restricted from exercise until resolution of symptoms and cardiac inflammation and confirmation of normal cardiac function and electrical stability.SummarySuspicion for VAM in athletes should be guided by clinical presentation and pretest probability. Evaluation and management of VAM are similar to that of viral myocarditis. Further longitudinal studies are needed to define the clinical course of VAM in athletic populations.
Source: Current Treatment Options in Cardiovascular Medicine - Category: Cardiology Source Type: research